

# Rosa De Vincenzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1152789/publications.pdf>

Version: 2024-02-01

54  
papers

2,124  
citations

236612

25  
h-index

233125

45  
g-index

55  
all docs

55  
docs citations

55  
times ranked

2520  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 459-464.                | 1.1 | 242       |
| 2  | Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells. <i>British Journal of Cancer</i> , 1990, 62, 942-946.                             | 2.9 | 125       |
| 3  | Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 255-258. | 1.1 | 120       |
| 4  | Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. <i>European Journal of Cancer</i> , 1996, 32, 877-882.  | 1.3 | 95        |
| 5  | Significance of epidermal growth factor receptor in advanced ovarian cancer.. <i>Journal of Clinical Oncology</i> , 1992, 10, 529-535.  | 0.8 | 89        |
| 6  | In vitro evaluation of newly developed chalcone analogues in human cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 305-312.   | 1.1 | 84        |
| 7  | EGF receptor expression in primary laryngeal cancer: Correlation with clinico-pathological features and prognostic significance. <i>International Journal of Cancer</i> , 1992, 52, 862-866.                                      | 2.3 | 83        |
| 8  | Long-term efficacy and safety of human papillomavirus vaccination. <i>International Journal of Women's Health</i> , 2014, 6, 999.   | 1.1 | 80        |
| 9  | Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth. <i>Anti-Cancer Drugs</i> , 1990, 1, 45-48.   | 0.7 | 65        |
| 10 | Management of an advanced ovarian cancer at 15 weeks of gestation: Case report and literature review. <i>Gynecologic Oncology</i> , 2005, 97, 693-696.  | 0.6 | 64        |
| 11 | Clinical Performance of Human Papillomavirus E6 and E7 mRNA Testing for High-Grade Lesions of the Cervix. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3895-3901.  | 1.8 | 63        |
| 12 | HPV vaccine cross-protection: Highlights on additional clinical benefit. <i>Gynecologic Oncology</i> , 2013, 130, 642-651.  | 0.6 | 61        |
| 13 | Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II). <i>Gynecologic Oncology</i> , 1992, 45, 13-19.  | 0.6 | 60        |
| 14 | Evaluation of quality of life and emotional distress in endometrial cancer patients: A 2-year prospective, longitudinal study. <i>Gynecologic Oncology</i> , 2014, 133, 518-525.  | 0.6 | 56        |
| 15 | Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study. <i>Gynecologic Oncology</i> , 2020, 159, 636-641.  | 0.6 | 54        |
| 16 | Quercetin induces type-II estrogen-binding sites in estrogen-receptor-negative (MDA-MB231) and estrogen-receptor-positive (MCF-7) human breast-cancer cell lines. <i>International Journal of Cancer</i> , 1993, 54, 462-466.     | 2.3 | 53        |
| 17 | Anti-proliferative activity of a new class of taxanes (14 <sup>β</sup> -hydroxy-10-deacetylbaicatin III derivatives) on multidrug-resistance-positive human cancer cells. , 1997, 72, 844-850.                                    |     | 51        |
| 18 | The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth. <i>Leukemia Research</i> , 1992, 16, 497-503.  | 0.4 | 49        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Significance of epidermal growth factor receptor expression in primary human endometrial cancer. <i>International Journal of Cancer</i> , 1994, 56, 26-30.   | 2.3 | 48        |
| 20 | Quercetin enhances transforming growth factor $\beta$ 21, secretion by human ovarian cancer cells. <i>International Journal of Cancer</i> , 1994, 57, 211-215.   | 2.3 | 42        |
| 21 | Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients. <i>British Journal of Cancer</i> , 2012, 107, 37-42.   | 2.9 | 40        |
| 22 | High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes. <i>Gynecologic Oncology</i> , 2021, 161, 173-178.   | 0.6 | 34        |
| 23 | Clinical significance of cathepsin D in primary ovarian cancer. <i>European Journal of Cancer</i> , 1994, 30, 935-940.   | 1.3 | 28        |
| 24 | Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison. <i>Vaccines</i> , 2020, 8, 717.                         | 2.1 | 28        |
| 25 | Development of a Nomogram Predicting the Risk of Persistence/Recurrence of Cervical Dysplasia. <i>Vaccines</i> , 2022, 10, 579.  | 2.1 | 27        |
| 26 | Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. , 1996, 68, 340-348.   |     | 26        |
| 27 | Health Utilities Lost and Risk Factors Associated With HPV-induced Diseases in Men and Women: The HPV Italian Collaborative Study Group. <i>Clinical Therapeutics</i> , 2015, 37, 156-167.e4.                | 1.1 | 26        |
| 28 | Which dimensions of health-related quality of life are altered in patients attending the different gynecologic oncology health care settings?. <i>Cancer</i> , 2002, 95, 2500-2507.                          | 2.0 | 25        |
| 29 | The role of sonographic examination in the follow-up of gynecological neoplasms. <i>Gynecologic Oncology</i> , 2005, 99, 696-703.  | 0.6 | 25        |
| 30 | Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours. <i>European Journal of Cancer</i> , 1992, 28, 1885-1889.   | 1.3 | 24        |
| 31 | Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanism. <i>Cancer Letters</i> , 1996, 108, 7-14.               | 3.2 | 22        |
| 32 | Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. <i>Annals of Oncology</i> , 2007, 18, 1348-1353.                                    | 0.6 | 22        |
| 33 | HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). <i>Vaccines</i> , 2020, 8, 354.   | 2.1 | 21        |
| 34 | Effects of dexamethasone on the growth and epidermal growth factor receptor expression of the OVCA 433 ovarian cancer cells. <i>Molecular and Cellular Endocrinology</i> , 1992, 83, 183-193.                | 1.6 | 19        |
| 35 | N-Deacetyl-N-aminoacylthiocolchicine Derivatives: Synthesis and Biological Evaluation on MDR-Positive and MDR-Negative Human Cancer Cell Lines. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 5272-5276. | 2.9 | 18        |
| 36 | Neoadjuvant chemotherapy followed by conization in stage IB2-IIA1 cervical cancer larger than 2 cm: a pilot study. <i>Fertility and Sterility</i> , 2021, 115, 148-156.                                      | 0.5 | 17        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Locally Advanced Cervical Cancer in Pregnancy: Overcoming the Challenge. A Case Series and Review of the Literature. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1490-1496.                                   | 1.2 | 16        |
| 38 | MRI in pregnant patients with suspected abdominal and pelvic cancer: a practical guide for radiologists. <i>Diagnostic and Interventional Radiology</i> , 2020, 26, 183-192.   | 0.7 | 16        |
| 39 | Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: Long-term results. <i>Gynecologic Oncology</i> , 2013, 128, 518-523.   | 0.6 | 14        |
| 40 | Treatment of cervical cancer in Italy: Strategies and their impact on the women. <i>Vaccine</i> , 2009, 27, A39-A45.   | 1.7 | 13        |
| 41 | Time Trade-Off Procedure for Measuring Health Utilities Loss With Human Papillomavirus-Induced Diseases: A Multicenter, Retrospective, Observational Pilot Study in Italy. <i>Clinical Therapeutics</i> , 2011, 33, 1084-1095.e4.  | 1.1 | 13        |
| 42 | Effect of age and cone dimensions on cervical regeneration: an Italian multicentric prospective observational study. <i>BMJ Open</i> , 2018, 8, e020675.   | 0.8 | 12        |
| 43 | Type II Estrogen-Binding Sites in Human Ovarian Cancer: Correlation with Estrogen, Progesterone, and Epidermal Growth Factor Receptor. <i>Gynecologic Oncology</i> , 1993, 49, 67-72.  | 0.6 | 9         |
| 44 | Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. <i>OncoTargets and Therapy</i> , 2014, 7, 1273.   | 1.0 | 9         |
| 45 | Are We Facing a New Colposcopic Practice in the HPV Vaccination Era? Opportunities, Challenges, and New Perspectives. <i>Vaccines</i> , 2021, 9, 1081.   | 2.1 | 8         |
| 46 | An acephalus acardius amorphous fetus in a monozygotic pregnancy with sex discrepancy. <i>Twin Research and Human Genetics</i> , 2006, 9, 697-702.   | 0.3 | 6         |
| 47 | Methyl-p-Hydroxyphenyllactate-esterase activity and type-II estrogen-binding sites in ovarian cancer: Correlation with biological and clinico-pathological parameters. <i>International Journal of Cancer</i> , 1995, 62, 536-541. | 2.3 | 4         |
| 48 | HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study. <i>Vaccines</i> , 2021, 9, 643.  | 2.1 | 4         |
| 49 | HPV Vaccination in Women Treated for Cervical Intraepithelial Neoplasia: A Budget Impact Analysis. <i>Vaccines</i> , 2021, 9, 816.   | 2.1 | 4         |
| 50 | Bowel Endometriosis with Hemoperitoneum Complicating Pregnancy. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 2013, 5, 166-169.  | 0.3 | 4         |
| 51 | Bisdioxopiperazine, (+)-1,2-Bis(3,5-Dioxopiperazinyl-1-yl)propane (ICRF 187), Enhances the Antiproliferative Effect of Cisplatin on Human Ovarian Cancer Cells. <i>Gynecologic Oncology</i> , 1995, 57, 16-22.                     | 0.6 | 3         |
| 52 | Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1141-1148.       | 1.2 | 3         |
| 53 | Reply to the letter to the editors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 449-450.   | 1.1 | 0         |
| 54 | NGR-hTNF and doxorubicin in relapsed ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5059-5059.  | 0.8 | 0         |